Loading
Obesity · Journal article
Molecular and Cellular Endocrinology · August 13, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a preclinical pharmacology study in diet-induced obese mice showing that compound 18, an N-salicyloyl tryptamine derivative, improved testicular histology and molecular markers of spermatogenesis, insulin sensitivity, and Sertoli cell glycolysis in a dose-dependent manner. The findings are mechanistic and exploratory; they do not yet establish efficacy, safety, or relevance in humans, and require confirmation in controlled studies with clinical endpoints.
Uncontrolled animal pharmacology study in diet-induced obese mice model. Male mice fed high-fat diet. Intervention: Compound 18 (N-salicyloyl tryptamine derivative) at 25 or 50 mg/kg.
Compound 18 at 25 and 50 mg/kg produced dose-dependent reductions in body weight, blood glucose, insulin levels, and lipid parameters in HFD-fed obese mice Testicular and epididymal tissue architecture were notably restored following compound 18 treatment PCNA (proliferation) was up-regulated; Bax was down-regulated and Bcl-2 was up-regulated, indicating reduced apoptosis
No human data, safety profile, or translation pathway provided
This preliminary work identifies compound 18 as a candidate for further investigation of HFD-induced male reproductive dysfunction. Any clinical translation would require controlled animal studies, toxicology, and human trials before use in patients.
Early-stage mechanistic study in an animal obesity model with surrogate endpoints and molecular markers, lacking human validation or clinical outcome data.
As stated by the source record.
Quoted from the source exactly as published.
This preliminary work identifies compound 18 as a candidate for further investigation of HFD-induced male reproductive dysfunction. Any clinical translation would require controlled animal studies, toxicology, and human trials before use in patients.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Objective. This study aimed to investigate the therapeutic potential of compound 18, an N-salicyloyl tryptamine derivative with established anti-neuroinflammatory and neuroprotective properties, in ameliorating male reproductive dysfunction induced by high-fat diet (HFD) in obese mice and to elucidate the underlying mechanisms.Methods. Male mice were fed a HFD to induce obesity and subsequently treated with compound 18 at doses of 25 or 50 mg/kg. Systemic metabolic parameters including body weight, blood glucose, insulin, and lipid profiles were measured. Histopathological assessments were conducted on liver, adipose tissue, testes, and epididymis. Molecular analyses were performed to evaluate the expression of markers related to proliferation (PCNA), apoptosis (BAX and Bcl-2), components of the insulin signaling pathway (IGF1, IGF1R), and key glycolytic enzymes (HK2, PKM2, LDHA).Results. Administration of compound 18 led to significant and dose-dependent improvements in systemic metabolism, characterized by reductions in body weight, blood glucose, insulin levels, and lipid parameters. The compound also attenuated hepatic steatosis and adipocyte hypertrophy, while notably restoring testicular and epididymal tissue architecture. At the molecular level, compound 18 up-regulated the proliferative marker PCNA, modulated apoptosis-related proteins (down-regulating Bax and up-regulating Bcl-2), enhanced insulin sensitivity-as indicated by increased IGF1R and decreased IGF1 expression-and augmented glycolytic capacity in Sertoli cells through elevated expression of HK2, PKM2, and LDHA.Conclusion. These results demonstrate that compound 18 effectively alleviates HFD-induced spermatogenic dysfunction concomitantly with ameliorating testicular insulin resistance and promoting glycolytic flux in Sertoli cells.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.